Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant

Gene Therapy

Volumn 6, Issue 8, 1999, Pages 1415-1426

  Kokoris, M S ^a   Sabo, P ^a   Adman, E T ^b   Black, M E ^a,c  

^a Chiroscience R and D Inc   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Herpes simplex virus type 1; Mutant; Suicide gene therapy; Thymidine kinase

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; THYMIDINE KINASE; VIRUS ENZYME;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG SENSITIVITY; ENZYME ACTIVE SITE; HERPES SIMPLEX VIRUS 1; NONHUMAN; PRIORITY JOURNAL; RAT; SUICIDE GENE; TUMOR MODEL; TUMOR XENOGRAFT;

ACYCLOVIR; AMINO ACID SEQUENCE; ANIMALS; GANCICLOVIR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOMA; HERPESVIRUS 1, HUMAN; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM TRANSPLANTATION; PRODRUGS; RATS; THYMIDINE KINASE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032820255     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300966     Document Type: Article

References (39)

1. Caruso M et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028.
2. Culver KW et al. In vivo gene transfer with retroviral vector-producing cells for treatment of experimental brain tumors. Science 1992; 256: 9575-9579.
3. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
4. Reardon JE. Herpes simplex virus type 1 and DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogs. Kinetics of incorporation into DNA and induction of inhibition. J Biol Chem 1989; 264: 19039-19044.
5. Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 1980; 255: 7204-7207.
6. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, phamacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990; 39: 597-638.
7. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
8. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
9. Colombo BM et al. The 'bystander effect': association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995; 6: 763-772.
10. Dilber MS et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 1997; 57: 1523-1528.
11. Tapscott SJ et al. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA 1994; 91: 8185-8189.
12. Black ME, Newcomb TG, Wilson H-MP, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA 1996; 93: 3525-3529.
13. Takamiya Y et al. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 1992; 33: 493-503.
14. Takamiya Y et al. An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 1993; 79: 104-110.
15. Chen S-H et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
16. Black ME, Rechtin TM, Drake RR. Effect on substrate binding of an alteration at the conserved aspartic acid-162 in herpes simplex virus type 1 thymidine kinase. J Gen Virol 1996; 77: 1521-1527.
17. Munir KM, French DC, Dube DK, Loeb LA. Permissible amino acid substitutions within the putative nucleoside binding site of herpes simplex virus type 1 established by random sequence mutagenesis. J Biol Chem 1992; 267: 6584-6589.
18. Balzarini J, Bohman C, De Clerq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem 1993; 268: 6332-6337.
19. Field AK et al. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy] methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 1983; 80: 4139-4143.
20. Brown DG et al. Crystal structure of the thymidine kinase from herpes simplex virus type-1 in complex with deoxythymidine and ganciclovir. Nature Struct Biol 1995; 2: 876-881.
21. Culver KW et al. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther 1994; 5: 334-379.
22. Kun LE, Gajjar A, Muhlbauer M. Sterotactic injection of herpes simplex virus thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther 1995; 6: 1231-1255.
23. Alvarez RD, Curiel DT. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Hum Gene Ther 1997; 8: 598-613.
24. Benda P et al. Differentiated rat glial cell strain in tissue culture. Science 1968; 161: 370-371.
25. Tiffany-Castiglioni E, Neck KF, Caceci T. Glial culture on artificial capillaries: electron microscopic comparisons of C6 rat glioma cells and rat astroglia. J Neurosci Res 1986; 16: 387-396.
26. Naus CC, Zhu D, Todd SD, Kidder GM. Characteristics of C6 glioma cells overexpressing a gap junction protein. Cell Mol Neurobiol 1992; 12: 163-175.
27. Black ME, Rechtin TM, Drake RR. Effect on substrate binding of an alteration at the conserved aspartic acid-162 in herpes simplex virus type 1 thymidine kinase. J Gen Virol 1996; 77: 1521-1527.
28. Shewach DS et al. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. Cancer Gene Ther 1994; 1: 107-112.
29. Aghi M et al. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5′ fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90: 370-380.
30. Harmenberg J. Intracellular pools of thymidine reduce the antiviral action of acyclovir. Intervirology 1983; 20: 48-51.
31. Balasubramaniam NK, Veerisetty V, Gentry GA. Herpesviral deoxythymidine kinases contain a site analogous to the phosphoryl-binding arginine-rich region of porcine adenylate kinase; comparison of secondary structure predictions and conservation. J Gen Virol 1990; 71: 2979-2987.
32. Ohno T et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury (see comments) Science 1994; 265: 781-784.
33. Cohen JL et al. Prevenction of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 1997; 89: 4636-4645.
34. Caruso M et al. Expression of a Tat-inducible herpes simplex virus-thymidine kinase gene protects acyclovir-treated CD4 cells from HIV-1 spread by conditional suicide and inhibition of reverse transcription. Virology 1995; 206: 495-503.
35. Hruby DE, Ball LA. Control of expresion of the vaccinia virus thymidine kinase gene. Virology 1981; 113: 594-601.
36. Segel IH. Biochemical Calculations, 2nd edn. John Wiley and Sons: New York, 1976.
37. Jones TA, Zou J-Y, Cowan SW, Kjeldgaard M. Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr 1991; A47: 110-119.
38. Kraulis P. A program to produce both detailed and schematic plots of protein structure. J Appl Cryst 1991; 24: 946-950.
39. Merritt EA, Murphy MEP. A program for photorealistic molecular graphics. Acta Crystallogr 1994; D50: 869-873.